WuXi Biologics (Cayman) Inc. (HKG: 2269)

Market Cap	76.61B
Revenue (ttm)	18.39B
Net Income (ttm)	2.83B
Shares Out	4.10B
EPS (ttm)	0.64
PE Ratio	29.01
Forward PE	18.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,460,113
Average Volume	37,057,186
Open	18.18
Previous Close	17.96
Day's Range	18.18 - 19.14
52-Week Range	10.14 - 32.25
Beta	0.57
RSI	59.02
Earnings Date	Mar 21, 2025

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 12,740
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2269

Financial Performance

In 2023, WuXi Biologics's revenue was 17.03 billion, an increase of 11.56% compared to the previous year's 15.27 billion. Earnings were 3.40 billion, a decrease of -23.09%.

Financial numbers in CNY